|
**Overview**: Breast Metastatic Marker Panel**Introduction**: The Breast Metastatic Marker Panel is a diagnostic tool designed to monitor breast cancer metastasis using serum samples. In India, breast cancer is the leading cancer in women (~178,000 cases/year), with metastatic disease in 5-10 percent at diagnosis and 30 percent developing later, high mortality due to late presentation. Markers (CA 15.3, CA 27.29, CEA, CA 125, AFP, Beta-hCG, HER2) aid monitoring response and recurrence. High morbidity from underdiagnosis in rural/low-SES patients, limited oncology access, delayed therapy escalation. Per oncology practices aligned with ICMR and Indian Society of Medical Oncology guidelines, the test employs immunoassay for marker analysis over 1-2 days with high sensitivity/specificity, valuable for surveillance in metastatic breast cancer. This diagnostic falls under cancer monitoring and targets patients with known breast cancer, addressing accurate detection to guide treatment adjustments. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise monitoring and improving survival. Its serum-based approach ensures reliable detection.**Other Names**: Breast Met Pnl.**FDA Status**: FDA approved, CLIA certified for oncology, compliant with 2025 standards.**Historical Milestone**: Tumor markers standard; in India, prominence with breast cancer burden.**Purpose**: The test monitors 7 parameters including CA 15.3 to guide metastatic breast cancer assessment, detect progression, inform therapy.**Test Parameters**: 1. CA 15.3, 2. CA 27.29, 3. CEA, 4. CA 125, 5. AFP, 6. Beta-hCG, 7. HER2.**Pretest Condition**: No fasting required; patients should report breast cancer history or symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on cancer stage, treatment, metastasis symptoms.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of metastatic progression, benefits of monitoring, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or concurrent illnesses can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Elevated markers indicate progression, necessitating specialist input. Normal may require follow-up if symptoms.**Specialist Consultation**: Oncologists should be consulted for management.**Additional Supporting Tests**: Imaging, biopsy for confirmation.**Test Limitations**: Markers may not be specific; comprehensive approach required.**References**: Indian Journal of Medical Oncology 2024, Breast Cancer Studies India 2023. |
